Table 3.

Adverse events occurring in >=10% of patients.

	Subjects - N(%) (Grades 1–2)		Subjects - N(%) (Grades 3–5)
	ASC (N = 51)	ASC+vinorelbine (N = 96)	ASC (N = 51)	ASC+vinorelbine (N = 96)
Blood and lymphatic system disorders
Anaemia	5 (10)	23 (24)	0 (0)	0 (0)
Lymphopenia	2 (4)	12 (12)	0 (0)	4 (4)
Neutropenia	0 (0)	6 (6)	0 (0)	12 (12)
Gastrointestinal disorders
Abdominal pain	1 (2)	13 (14)	0 (0)	2 (2)
Constipation	4 (8)	37 (39)	0 (0)	1 (1)
Diarrhoea	2 (4)	24 (25)	0 (0)	0 (0)
Nausea	2 (4)	22 (23)	0 (0)	0 (0)
General disorders and administration site conditions
Fatigue	11 (22)	46 (48)	0 (0)	4 (4)
Chest Pain	5 (10)	12 (12)	0 (0)	2 (2)
Infections and infestations
Lower respiratory infection	3 (6)	6 (6)	3 (6)	5 (5)
Metabolism and nutrition disorders
Anorexia	5 (10)	22 (23)	0 (0)	0 (0)
Respiratory, thoracic and mediastinal disorders
Coughing	12 (24)	21 (22)	0 (0)	0 (0)
Dyspnoea	9 (18)	25 (26)	0 (0)	6 (6)